Entrada Therapeutics, Inc. (TRDA)
TRDANASDAQ-GMBiotechnology: Pharmaceutical Preparations
$5.44
0.0000 (0.00%) today
Pre-market, Nov 11, 4:00 PM ET
- Market cap
- $212.98m
- P/E
- –
- EPS, last 4 quarters
- $-3.84
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.11 to $16.45
- Average volume
- –
- Previous close
- $5.44
Analysts
4 coveringBuy3 buy, 1 hold, 0 sell
Targets a year out average $19.33, +255.3% from here
Earnings
next estimate $-1.23Next report
Dec 2025
+28.8%
Mar 2026
+10.4%
Jun 2026
+12.9%
Sep 2026
+4.1%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $1.30m | $875.0k | $898.0k | $905.0k |
| Gross profit | $1.30m | $875.0k | $898.0k | $905.0k |
| Operating income | -$42.21m | -$42.30m | -$44.96m | -$41.69m |
| Net income | -$39.16m | -$39.72m | -$42.76m | -$39.74m |
Last four quarters: revenue $3.98m, margin -4058.0%, free cash flow -$136.33m
News
8 latest- Entrada Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · 7 days ago
- Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue EstimatesZacks · 7 days ago
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data RTTNews · Oct 16, 2026
- Noteworthy Thursday Option Activity: TRDA, JBS, MCRIBNK Invest · Oct 15, 2026
- Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level RTTNews · Oct 14, 2026
- Entrada Reports Positive Topline Data From Cohort 1 Of Phase 1/2 ELEVATE-45-201 Study Of ENTR-601-45 RTTNews · Oct 14, 2026
- Entrada Q2 Loss Shrinks; Data From Phase 1/2 Trials In DMD And DM1 Expected In '27 RTTNews · Aug 7, 2026
- Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue EstimatesZacks · Aug 5, 2026
The company
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- entradatx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.